Skip to content
type1.science
Phase 1Not yet recruitingNCT07610213

MATIN-2: teplizumab, intralymphatic insulin and low-dose IL-2

Sequential combination protocol for recent-onset T1D: teplizumab induction, intralymphatic insulin immunotherapy, and low-dose IL-2 maintenance to combine immune quieting with antigen-specific tolerance.

Primary endpoints

  • Change in stimulated C-peptide AUC

Results so far

No results posted yet.